Bextra Withdrawn From Market – VanDerGinst Law Investigates Potential Claims
On April 7, 2005, Pfizer suspended all sales of the popular pain killer Bextra in the United States and the European Union after the Food and Drug Administration (FDA) announced that the overall risk versus benefit of Bextra is unfavorable.
The drug is made by Pfizer, the world’s largest drugmaker, which denies any problem exists with Bextra. However, in a statement on April 7, 2005, Pfizer stated that “For now, patients should stop taking Bextra and contact their physicians about appropriate treatment options.”
VanDerGinst Law has been investigating potential claims against Pfizer for injuries caused by the use of Bextra for many months. Managing partner, Dennis VanDerGinst, said in a recent statement, “Our firm is working with a consortium of law firms from across the country to identify victims and represent their interests in hopes of obtaining reasonable compensation.”
The decision to withdraw Bextra, from the market was based on an increase in adverse cardiovascular events shown in Bextra trials, reports of serious and potentially life-threatening skin reactions, including deaths, and lack of any demonstrated advantages for Bextra compared with other non-steroidal anti-inflammatory drugs (NSAIDs).
Bextra (Valdecoxib), may be linked to increased heart attack and stroke risks. Bextra is in the same class of drugs as Vioxx which was withdrawn after studies showed it was too dangerous. These drugs are both Cox 2 Inhibitors, a drug class that many researchers believe interferes with the body’s natural ability to reduce blood clots, thereby increasing heart risks. Many doctors believe Bextra presents the same or similar risks as Vioxx.
In addition to being linked to an increase in heart attacks and strokes, Bextra is associated with a skin disorder called Stevens-Johnson Syndrome or “SJS”. Stevens-Johnson Syndrome is a severe allergic reaction and is potentially life-threatening.
A November 2004 study, presented to the American Heart Association indicates that patients who take Bextra are more than twice as likely (as non-users) to suffer heart attacks or stroke. The study involved 5,930 patients, some taking Bextra and some given a placebo.
Dr. Garret A. FitzGerald, the University of Pennsylvania cardiologist who presented the study to the AHA was quoted in The New York Times saying: “This is a time bomb waiting to go off… The magnitude of the signal with Bextra is even higher than what we saw in Vioxx.”
Contact VanDerGinst Law if you have been affected. We have knowledgeable and experienced attorneys who can help guide you through the complexities of your case and help you obtain the financial compensation you deserve. The consultation is free and there is never a fee unless we win. Call VanDerGinst Law at 800-797-5391. The law is tough, being injured is tougher. We’ll make it easier for you.
The information contained on this website is presented by VanDerGinst Law P.C. It is not intended nor should it be construed as professional legal advice. The information is general in nature about the Firm, the scope of services we offer, and our community outreach, it is not legal advice. Please contact us by phone, email, mail, or via this website for inquiries. Contacting us does not create an attorney-client relationship. Please contact a personal injury attorney for a consultation regarding your situation. This website is not intended to solicit clients outside the State of Iowa and/or the State of Illinois.